Metabolon signed a contract to support the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) in its investigation into he AVA anthrax vaccine.
This is the only FDA-licensed anthrax vaccine for humans. The company’s metabolomics platform will be used to study the biochemical profiles of humans given the vaccine.
“This collaboration represents the first large-scale metabolomics study of human subjects given a vaccine,” notes Mike Milburn, Metabolon’s CSO. “This type of comprehensive biochemical profiling will help USAMRIID better understand the vaccine’s safety, efficacy, and mechanism of action.”
